CID (Carbostent & Implantable Devices) announced on 6 April 2010 that it has signed an agreement to acquire Datascope’s Peripheral Vascular Stents Assets, including intellectual property.
This acquisition allows CID to extend its portfolio to the large peripheral vascular products field, including self- and balloon-expandable stents and angioplasty catheters. CID has now the full ownership of the know-how and intellectual property of the entire stent and catheter angioplasty field, both coronary and peripheral.
Franco Vallana, CID’s CEO is proud of this acquisition, just after one year from the foundation of the Company, and he considers this as the first stage to access a new market with huge opportunities. “This important step”, Franco Vallana said, “shows the quality and consistence of CID project confirming this company as an inspiring reality patient driven solutions”.
CID is dedicated to contributing to human welfare by improving the quality of patient care and after-care through the development of innovative, minimally invasive implantable devices, procedures and therapies.
A strong background in the field of implantable cardiovascular devices and haemocompatible materials, expressed in a remarkable IP portfolio, and a management with an expertise gained in many years of research, development and clinical experience, allow CID to offer the investors a fair return and its customers the necessary tools to meet new challenges.